PATANASE (olopatadine hydrochloride) Nasal Spray
PATANASE (olopatadine hydrochloride) Nasal Spray, 665 micrograms (mcg) is a metered-spray solution for intranasal administration. Olopatadine hydrochloride, the active component of PATANASE Nasal Spray, is a white, water-soluble crystalline powder.
PATANASE Nasal Spray is indicated for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older.
Published Studies Related to Patanase (Olopatadine Nasal)
Comprehensive report of olopatadine 0.6% nasal spray as treatment for children with seasonal allergic rhinitis. [2011.05]
Allergic rhinitis (AR) is highly prevalent in children...
Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis. [2011.03]
Olopatadine hydrochloride nasal spray 0.6% (OLO) and azelastine nasal spray 137 micrograms (AZE) are effective in treating allergic rhinitis and AZE is indicated for nonallergic vasomotor rhinitis (VMR). This study evaluates the relative safety and efficacy of OLO and AZE in patients with VMR.
Mometasone furoate nasal spray for moderate-to-severe nasal congestion in
subjects with seasonal allergic rhinitis. 
Nasal congestion is a frequent, bothersome symptom of seasonal allergic rhinitis
(SAR). Mometasone furoate nasal spray (MFNS) has established efficacy in treating
nasal allergy symptoms, but no study has been conducted with the primary purpose
of evaluating MFNS for relief of congestion...
Olopatadine hydrochloride in children: efficacy and safety for perennial allergic rhinitis. [2010.07]
OBJECTIVE: The efficacy of antihistamines in perennial allergic rhinitis in children has been evaluated in studies using active comparators, whereas placebo-controlled studies are very few. A randomized, multicenter, double-blind, parallel-group clinical study was carried out to evaluate the dose-response relationship and superiority of olopatadine hydrochloride over placebo in children aged 7 to 16 years with perennial allergic rhinitis... CONCLUSIONS: Olopatadine hydrochloride 5 mg twice daily is an effective and safe treatment for perennial allergic rhinitis in children.
Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis. [2010.03]
The combination of intranasal antihistamines and intranasal corticosteroids results in superior relief of seasonal allergic rhinitis (SAR) symptoms compared with monotherapy. This study was designed to evaluate the safety and efficacy of olopatadine hydrochloride nasal spray, 0.6% (OLO), administered in combination with fluticasone nasal spray, 50 micrograms (FNS), relative to azelastine nasal spray, 0.1% (AZE), administered in combination with FNS in the treatment of SAR.
Clinical Trials Related to Patanase (Olopatadine Nasal)
Comparing Patient Satisfaction With Pataday or Bepreve [Recruiting]
The purpose of this study is to compare patient satisfaction with Pataday (Olopatadine
hydrochloride 0. 2%) one daily (QD) and Bepreve (Bepotastine besilate ophthalmic solution
1. 5%) two times a day (BID).
Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis [Recruiting]
The purpose of this study is to evaluate an ophthalmic solution for the treatment of ocular
itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge
Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis [Not yet recruiting]
The purpose of this study is to evaluate the clinical efficacy of the ophthalmic solution
PRO-118 compared with olopatadine hydrochloride ophthalmic solution in allergic
Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients [Recruiting]
Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age [Recruiting]
The purpose of the study is to assess the safety of the study drug, Patanase (Olopatadine
Hydrochloride Nasal Spray 0. 6%) compared to placebo (inactive substance) in children ages 2
to less than 6 who have a history of nasal allergies, and to assess the pharmcokinetics
(study of the action of a drug in the body) in these children